store at low temperature,keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NADPH tetrasodium salt [2646-71-1]
Referencia T7092-200mg
embalaje : 200mg
Marca : TargetMol
Contact local distributor :
Teléfono : +1 850 650 7790
NADPH tetrasodium salt
Catalog No. T7092 CAS 2646-71-1
NADPH tetrasodium salt is the reduced form of the electron acceptor nicotinamide adenine dinucleotide phosphate, which acts as an electron donor in a variety of biological reactions. NADPH tetrasodium salt is also an endogenous inhibitor of iron death.
All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.
NADPH tetrasodium salt, CAS 2646-71-1
| Description | NADPH tetrasodium salt is the reduced form of the electron acceptor nicotinamide adenine dinucleotide phosphate, which acts as an electron donor in a variety of biological reactions. NADPH tetrasodium salt is also an endogenous inhibitor of iron death. |
| In vitro | METHODS: Neurons were pretreated with NADPH tetrasodium salt (2.5-10 μM) for 1-8 h, then treated with Kainic acid (KA, 100 μM) for 8 h. Cell viability was measured by CCK-8 assay. RESULTS: KA treatment significantly reduced the cell viability of primary cortical neurons in a time-dependent and dose-dependent manner, and NADPH pretreatment significantly promoted neuronal survival, which was more effective at 10 μM for 4 or 8 h. The RESULTS showed that Kainic acid (KA, 100 μM) treatment significantly reduced the cell viability of primary cortical neurons. [1] METHODS: Neurons were pretreated with NADPH tetrasodium salt (10 μM) for 4 h, and then treated with Kainic acid (KA, 100 μM) for 8 h. The expression levels of target proteins were detected by Western Blot. RESULTS: The expression of TIGAR was decreased after KA treatment, and it was significantly reversed by NADPH. [1] |
| In vivo | METHODS: To examine the effects on Kainic acid (KA)-induced excitotoxicity and its mechanism, NADPH tetrasodium salt (1-2 mg/kg in saline) was administered intravenously to KA-induced rats once a day for seven days. RESULTS: NADPH reduced KA-induced increase in striatal lesion size, improved KA-induced dyskinesia, and reversed KA-induced glial cell activation. [1] METHODS: NADPH tetrasodium salt (2.5 mg/kg) was intravenously injected into ICR mice to determine whether exogenous NADPH could enter the brain tissues and neurons of mice. RESULTS: Injection of NADPH significantly increased the levels of NADPH in the blood and brain tissue of mice.The half-life of NADPH in the blood of mice is about 6 h and in the brain tissue is 7 h. [2] |
| Molecular Weight | 833.35 |
| Formula | C21H26N7Na4O17P3 |
| CAS No. | 2646-71-1 |
Storage
Solubility Information
DMSO: 1.25 mg/mL (1.5 mM), Sonication is recommended.
H2O: 35 mg/mL (42.00 mM)
References and Literature
1. Liu ZQ, et al. NADPH protects against kainic acid-induced excitotoxicity via autophagy-lysosome pathway in rat striatum and primary cortical neurons. Toxicology. 2020 Apr 15;435:152408. 2. Li M, et al. Reduced Nicotinamide Adenine Dinucleotide Phosphate, a Pentose Phosphate Pathway Product, Might Be a Novel Drug Candidate for Ischemic Stroke. Stroke. 2016 Jan;47(1):187-95.